sra-21 Antibody

What is SRA and why is it significant in immunological research?

Scavenger Receptor A (SRA, also known as CD204) functions as an innate pattern recognition receptor (PRR) primarily expressed on myeloid-origin cells including dendritic cells (DCs) and macrophages. It exhibits pleiotropic biological and pathological activities due to its ability to bind a broad spectrum of ligands and macromolecules . Significantly, SRA acts as an immunosuppressive regulator that dampens the immunostimulatory function of dendritic cells in promoting T cell-mediated antitumor immunity . This characteristic makes SRA a critical target in immunotherapy research, as inhibiting this immunosuppressor may enhance DC functionality for T cell priming and improve DC-targeted cancer immunotherapies . Additionally, SRA serves as a phenotypic marker for alternatively activated (M2-like) macrophages and plays a role in the functional regulation of tumor-associated macrophages that promote cancer progression .

How do researchers distinguish between different SRA expression patterns in various cell types?

Researchers typically employ multiple complementary techniques to distinguish SRA expression patterns across different cell populations. Flow cytometry using fluorescently labeled anti-SRA antibodies allows for quantitative assessment of SRA surface expression on specific cell populations identified through additional markers (e.g., CD11c for dendritic cells). Immunohistochemistry and immunofluorescence microscopy enable visualization of SRA distribution in tissue sections, providing spatial context to expression patterns. Quantitative PCR for SRA mRNA quantification allows measurement of transcriptional regulation across different cell types.

How does SRA silencing enhance the immunogenicity of dendritic cells in chaperone vaccine research?

Short hairpin RNA (shRNA)-mediated SRA silencing significantly enhances the immunostimulatory activity of dendritic cells (DCs) following their interaction with chaperone vaccines. When DCs with reduced SRA expression capture chaperone vaccines like hsp110-gp100 (tested in melanoma models) or hsp110-HER/Neu-ICD (for breast cancer), they demonstrate markedly improved capacity to stimulate antigen-specific T cells .

The mechanism involves several key processes:

• SRA-silenced DCs pulsed with chaperone vaccines show increased efficiency in stimulating the proliferation of antigen-specific CD8+ T cells, as demonstrated by CFSE dilution assays .

• In vivo, SRA-silenced DCs exhibit greater immunogenicity when presenting chaperone vaccines, resulting in significant increases in IFN-γ-producing antigen-specific T cells as measured by intracellular cytokine staining and flow cytometry .

• The enhanced immunogenicity translates to improved cytotoxic T lymphocyte (CTL) activity against target cells, as demonstrated in in vivo CTL assays where immunization with SRA-silenced DCs resulted in higher efficiency of antigen-specific killing compared to mock-treated DCs .

This enhancement in DC function through SRA silencing represents a promising strategy for improving the efficacy of chaperone-based cancer vaccines in stimulating potent antitumor immune responses.

What methodological approaches are most effective for inhibiting SRA in experimental models?

Research demonstrates two primary methodological approaches for inhibiting SRA in experimental models, each with distinct applications and considerations:

1. shRNA-Mediated Gene Silencing:
Lentiviral vectors encoding SRA-specific shRNA provide stable, long-term SRA knockdown in dendritic cells . This approach is particularly valuable for ex vivo modification of DCs prior to their use in adoptive transfer experiments. The technique allows for consistent SRA suppression throughout the experimental timeframe, facilitating studies on DC functionality in vitro and in vivo. Flow cytometry confirmation of knockdown efficiency is essential before proceeding with functional assays.

2. siRNA with Biodegradable Carriers:
Small interfering RNA (siRNA) complexed with biodegradable, biocompatible carriers like chitosan can efficiently reduce SRA expression on CD11c+ dendritic cells both in vitro and in vivo . This approach offers the advantage of direct administration to experimental animals, bypassing the need for ex vivo cell manipulation. The chitosan-siRNA complex enables targeted delivery to DCs and promotes chaperone vaccine-elicited cytotoxic T lymphocyte responses, improving tumor control in experimental models .

When selecting between these approaches, researchers should consider: (1) the duration of SRA inhibition required, (2) whether in vivo or ex vivo application is preferred, (3) the specific research question being addressed, and (4) available technical capabilities. Both approaches have demonstrated efficacy in enhancing DC immunogenicity and subsequent antitumor immune responses.

How does SRA inhibition affect the tumor microenvironment in experimental cancer models?

SRA inhibition profoundly reprograms the tumor microenvironment, transforming it from immunosuppressive to immunostimulatory. Research demonstrates that treatment with SRA-silenced dendritic cells carrying chaperone vaccines induces several significant changes within the tumor microenvironment:

• Transcriptional Reprogramming: There is significant upregulation of ifng (interferon gamma) gene expression in tumor tissues from mice receiving SRA-silenced DCs carrying the hsp110-gp100 vaccine, while no changes are observed in tnfb (lymphotoxin-α) or il10 expression . This selective gene modulation indicates a shift toward Th1-dominant immunity.

• Increased IFN-γ Production: Tissue ELISA analysis confirms elevated levels of IFN-γ protein within tumor sites . This cytokine is a signature of Th1 immunity critical for tumor suppression and elimination.

• Enhanced Immune Cell Infiltration: Tumors from mice treated with SRA-silenced DCs demonstrate increased infiltration of CD8+ T cells and natural killer (NK) cells, both known for their IFN-γ-producing capacity and antitumor functions .

• Augmented Tumor Cell Death: The enhanced immune activation correlates with increased cancer cell death, as evidenced by TUNEL assays showing greater apoptotic activity within tumors .

• Cytokine Profile Alterations: Beyond IFN-γ, treatment with SRA siRNA combined with chaperone vaccines leads to elevations in IL-12 and potentially other pro-inflammatory cytokines that collectively support antitumor immunity .

These findings demonstrate that SRA inhibition not only enhances DC functionality but also transforms the tumor microenvironment to favor immune-mediated tumor control, representing a promising strategy for cancer immunotherapy.

What are the key protocols for evaluating SRA-silenced dendritic cells in cancer vaccine research?

Comprehensive Protocol Suite for SRA-Silenced DC Evaluation

To rigorously assess the functionality of SRA-silenced dendritic cells in cancer vaccine research, researchers should implement the following integrated protocols:

• Verification of SRA Knockdown Efficiency:

  • Quantify SRA expression reduction via flow cytometry using fluorescently-labeled anti-SRA antibodies

  • Confirm at protein level through Western blotting

  • Validate knockdown at mRNA level using quantitative RT-PCR

• In Vitro T Cell Stimulation Assays:

  • CFSE dilution assay: Co-culture SRA-silenced DCs pulsed with chaperone vaccines (e.g., hsp110-gp100) with CFSE-labeled antigen-specific CD8+ T cells

  • Measure T cell proliferation through progressive CFSE dilution via flow cytometry

  • Analyze T cell activation markers (CD25, CD69) and effector cytokines (IFN-γ, TNF-α) by flow cytometry

• In Vivo T Cell Priming Assessment:

  • Adoptively transfer antigen-specific T cells (e.g., gp100-specific CD90.1+ Pmel cells) to experimental animals

  • Immunize with SRA-silenced DCs loaded with relevant chaperone vaccines

  • Evaluate T cell expansion, activation status, and cytokine production through:

    • Flow cytometric analysis of lymphoid tissues

    • Intracellular cytokine staining for IFN-γ production

    • ELISPOT assays to enumerate antigen-specific IFN-γ-producing cells

• Cytotoxic Function Evaluation:

  • Perform in vivo CTL assays using differentially CFSE-labeled target cells (peptide-pulsed CFSEhigh and unpulsed CFSElow cells at 50:50 ratio)

  • Determine specific killing by analyzing the ratio of remaining target populations

• Therapeutic Efficacy Assessment:

  • Establish tumor models (e.g., B16-gp100 melanoma)

  • Treat with SRA-silenced DCs carrying appropriate chaperone vaccines

  • Monitor tumor growth kinetics and survival outcomes

  • Analyze tumor-infiltrating lymphocyte populations by flow cytometry or immunohistochemistry

  • Assess tumor microenvironment changes through gene expression analysis and tissue ELISA for key cytokines

These protocols should be performed with appropriate controls, including mock-treated DCs and/or scramble shRNA-treated DCs, to establish the specific effects of SRA silencing on DC functionality and subsequent antitumor immune responses.

How can researchers effectively design comparative studies between SRA-targeted therapies and conventional immunotherapies?

Designing rigorous comparative studies between SRA-targeted therapies and conventional immunotherapies requires careful consideration of multiple experimental parameters. The following framework provides a methodological approach:

Study Design Elements:

This structured approach allows for comprehensive comparison between SRA-targeted approaches and conventional immunotherapies, providing insights into their relative efficacy, mechanisms of action, and potential synergistic effects when combined.

Beyond cancer, what other disease models may benefit from research on SRA antibodies?

While current research primarily focuses on SRA inhibition in cancer immunotherapy, the fundamental role of SRA in immune regulation suggests potential applications across multiple disease models:

Autoimmune Diseases
SRA functions at the interface of innate and adaptive immunity, potentially influencing autoimmune pathogenesis. Research indicates that SS-A/Ro antibodies (distinct from but related to SRA research methodologies) are prevalent in various autoimmune conditions including primary Sjögren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic sclerosis, and inflammatory myopathies . The methodology developed for SRA research could be adapted to study these autoimmune conditions, particularly focusing on how modulating SRA activity might influence autoantibody production or autoimmune inflammation.

Infectious Diseases
As a pattern recognition receptor, SRA recognizes various pathogen-associated molecular patterns. Research into SRA antibodies could illuminate how SRA modulation affects pathogen clearance and immune responses during infection. The methodologies used for evaluating T cell responses in cancer models following SRA inhibition could be adapted to study pathogen-specific T cell responses.

Inflammatory Disorders
Given SRA's role in regulating macrophage polarization (serving as a marker for M2-like macrophages) , SRA antibody research could provide insights into inflammatory diseases where macrophage polarization plays a central role, such as atherosclerosis, inflammatory bowel disease, and neurodegenerative disorders.

Transplantation and Graft-versus-Host Disease
The immunoregulatory functions of SRA suggest potential applications in transplant rejection and graft-versus-host disease models. Researchers could investigate whether SRA modulation affects allorecognition and transplant outcomes.

Pulmonary Disorders
Evidence suggests SRA relevance as a prognostic marker for interstitial lung disease in patients with interstitial pneumonia with autoimmune features (IPAF), systemic sclerosis, SLE, and inflammatory myopathies . The methodologies developed for SRA antibody research in cancer could be applied to study these pulmonary conditions.

For these alternative disease models, researchers should adapt the protocols developed for cancer research, including SRA silencing methods, immune profiling strategies, and functional assays, to address disease-specific questions while maintaining methodological rigor.

How do research methodologies for studying SS-A/Ro antibodies differ from those for SRA antibodies?

The methodologies for studying SS-A/Ro antibodies and SRA (Scavenger Receptor A) antibodies differ significantly in their technical approaches, applications, and interpretations due to their distinct biological contexts. Understanding these differences is crucial for researchers designing experiments in either field:

Target and Biological Context:

• SS-A/Ro Antibodies: These are autoantibodies directed against components of the Ro/La heterogeneous antigenic complex, specifically the 52 kDa (Ro52) and 60 kDa (Ro60) proteins . They are biomarkers of autoimmune diseases and part of the patient's immune response against self-antigens.

• SRA Antibodies: These target the Scavenger Receptor A (CD204) expressed on myeloid cells . They are research or therapeutic tools used to study or modulate SRA function.

Detection Methodologies:

For SS-A/Ro Antibodies:

• Multiplex Bead Assays: Allow simultaneous detection of multiple autoantibodies in patient serum

• Chemiluminescence Immunoassays: Offer separate detection of Ro52 and Ro60 antibodies with high sensitivity

• Indirect Immunofluorescence Assay (IFA): Using HEp-2 substrate to identify characteristic nuclear fine speckled pattern (AC-4) associated with SS-A/Ro antibodies

• Solid Phase Immunoassays: Used for screening following positive ANA results

• Connective Tissue Cascade Testing: Incorporating SS-A antibody testing in a diagnostic algorithm

For SRA Antibodies:

• Flow Cytometry: To quantify SRA expression on specific cell populations like dendritic cells

• Western Blotting: For total protein level assessment before and after interventions

• Immunohistochemistry: To visualize SRA distribution in tissue sections

• RNA Interference Techniques: Including shRNA and siRNA approaches to study SRA function through knockdown

• Functional Assays: To evaluate the impact of SRA modulation on immune cell function, such as T cell activation assays

Clinical vs. Research Applications:

• SS-A/Ro antibody testing focuses on clinical diagnosis, prognosis, and stratification of patients with autoimmune diseases

• SRA antibody research primarily addresses experimental immunology questions and potential immunotherapeutic applications

Reporting Considerations:

• SS-A/Ro antibody testing requires careful consideration of how results are reported (together or separately for Ro52 and Ro60) as this has implications for diagnosis and disease classification

• SRA research reporting focuses on functional outcomes of SRA modulation rather than mere detection

These methodological differences highlight the importance of selecting appropriate experimental approaches based on whether the research focuses on autoantibody biomarkers (SS-A/Ro) or immune receptor modulation (SRA).

What emerging technologies might improve the specificity and effectiveness of SRA targeting in immunotherapy?

Several emerging technologies hold promise for enhancing the specificity and effectiveness of SRA targeting in immunotherapy research:

1. Targeted Delivery Systems
Nanoparticle-based delivery platforms can significantly improve SRA targeting specificity. Biodegradable, biocompatible carriers like chitosan have already demonstrated efficacy in delivering siRNA to target SRA on CD11c+ dendritic cells both in vitro and in vivo . Future developments may include:

• Lipid nanoparticles with DC-specific targeting ligands

• Polymeric micelles designed for controlled release of SRA-targeting agents

• Exosome-based delivery systems that inherently target specific immune cell populations

• Click chemistry approaches for in vivo conjugation and improved targeting

2. Advanced Genetic Modification Approaches
Beyond conventional RNA interference methods:

• CRISPR-Cas9 gene editing for precise SRA knockout in specific cell populations

• CRISPRi for tunable, reversible SRA repression

• RNA-targeting CRISPR systems for transient SRA mRNA knockdown with reduced off-target effects

• Synthetic biology approaches using logic gates to control SRA expression in response to specific tumor microenvironment signals

Antibody Engineering Technologies

• Bispecific antibodies that simultaneously target SRA and activate costimulatory pathways

• Antibody-drug conjugates that deliver immunomodulatory agents specifically to SRA-expressing cells

• Intrabodies designed to target and inhibit SRA intracellularly

• Nanobodies with enhanced tissue penetration for improved access to SRA-expressing cells in solid tumors

Advanced Imaging for Monitoring SRA Targeting

• Intravital microscopy to visualize SRA-targeting in real-time in vivo

• PET reporter systems to track SRA-targeting agent biodistribution

• Mass cytometry (CyTOF) for high-dimensional analysis of SRA expression and function

• Spatial transcriptomics to map SRA expression and activity within the complex tissue architecture

Combination Therapy Approaches

• Integration of SRA targeting with immune checkpoint blockade

• Sequential immunotherapeutic regimens that prime with SRA inhibition

• Rational design of multi-targeted approaches addressing complementary immunosuppressive mechanisms

• Computational modeling to predict optimal combination strategies based on patient-specific immune parameters

These emerging technologies, particularly when used in combination, hold significant promise for increasing both the specificity and effectiveness of SRA targeting in next-generation immunotherapeutic approaches.

How might integrative data analysis approaches improve our understanding of SRA function in different immune contexts?

Integrative data analysis approaches can significantly enhance our understanding of SRA function across diverse immune contexts by synthesizing multi-omics data and implementing advanced computational methods. These approaches enable researchers to uncover complex patterns and mechanisms that may not be apparent through traditional single-method analyses.

Multi-Omics Integration Strategies

• Combined Transcriptomic and Proteomic Analysis:
  Correlating SRA expression at mRNA and protein levels across different immune cell populations can reveal post-transcriptional regulatory mechanisms affecting SRA function. Studies demonstrate that dual positivity for related autoantibodies (Ro52 and Ro60) versus single positivity correlates with different autoimmune disease presentations , suggesting that integrative approaches could similarly uncover patterns in SRA expression across different immune contexts.

• Spatial Transcriptomics and Proteomics:
  These technologies enable mapping of SRA expression and activation patterns within tissue microenvironments, providing context-specific information about SRA function. This approach could extend findings about how SRA inhibition reprograms the tumor environment by revealing spatial relationships between SRA-expressing cells and other immune populations.

• Single-Cell Multi-Omics:
  Combining single-cell RNA sequencing with protein measurements allows identification of distinct cell states associated with SRA expression and function. This could help categorize subpopulations of dendritic cells with differential SRA expression and activity, building on observations about how SRA silencing affects DC immunostimulatory capacity .

Advanced Computational Methods

• Network Analysis Approaches:

  • Construct protein-protein interaction networks centered on SRA to identify context-specific binding partners

  • Apply gene regulatory network analysis to uncover transcription factors controlling SRA expression in different immune states

  • Use pathway enrichment analysis to identify biological processes affected by SRA modulation

• Machine Learning Applications:

  • Develop predictive models for therapeutic responses to SRA-targeted therapies

  • Apply unsupervised learning to identify novel patterns in SRA expression across immune contexts

  • Implement deep learning approaches to integrate complex, multi-dimensional data related to SRA function

• Systems Biology Frameworks:

  • Create mathematical models of SRA signaling dynamics across immune cell types

  • Develop agent-based models simulating SRA-expressing cell interactions in different tissue environments

  • Apply ordinary differential equation models to predict outcomes of SRA targeting in various immune contexts

Translational Data Integration

Connecting experimental findings with clinical data through:

• Integration of SRA expression data with patient outcome information

• Correlation of SRA functional metrics with treatment response profiles

• Development of SRA-based immune signatures with prognostic or predictive value

These integrative approaches would extend current understanding by connecting molecular-level SRA function to cellular, tissue, and organism-level immune responses, potentially revealing new therapeutic opportunities and mechanistic insights across diverse immune-mediated conditions.